// App-Quantinova.ai

BSH2020‐PO‐011 : Combination therapies targeting DNA damage signalling as a therapeutic strategy in acute myeloid leukaemia

Researchers

Presenter

  • L. Monaghan

Principal Investigators

  • R. P. Bunschoten

  • S. Gannon

  • A. Hoose

  • P.-A. Pirvan

  • T. Park

  • J. Bittencourt - Silvestre

  • R. Liskamp

  • H. Jrgensen

  • X. Huang

Medical Centers

  • Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow

  • School of Chemistry, Joseph Black Building , University of Glasgow, Glasgow, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Cluster of Differentiation 34

  • Protein AF-9

  • Fms related tyrosine kinase 3

  • Histone-lysine N-methyltransferase 2A

  • Interleukin 13

  • Interleukin 4

Drug/Treatment

  • ribose

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved